- Home
- ABOS vs SAVA Comparison
ABOS vs SAVA Comparison
Compare ABOS & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | SAVA |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.5M | 103.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABOS | SAVA |
|---|---|---|
| Price | $1.85 | $2.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $7.67 | $5.00 |
| AVG Volume (30 Days) | 220.8K | ★ 1.0M |
| Earning Date | 11-12-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $1.15 |
| 52 Week High | $2.46 | $4.98 |
Technical Indicators
Market Signals| Indicator | ABOS | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 35.82 |
| Support Level | $1.67 | $1.96 |
| Resistance Level | $1.99 | $2.19 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 38.30 | 15.62 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.